Organoids cannot replace physiology in cancer drug development.

Authors

João Conde

Published in

Trends in biotechnology. Aug 11, 2026. Epub Aug 11, 2026.

Abstract

Regulators are accelerating new approach methodologies in cancer drug development. Their capacity to replace animal studies should depend on the context of use. Organoids, chips, and computational models can answer local, measurable questions, whereas whole-body biodistribution, immune handling, organ clearance, chronic toxicity, and therapeutic index still require integrated physiological evidence.

PMID:
42580939
Bibliographic data and abstract were imported from PubMed on 12 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.